Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Oct;38(4):323–328. doi: 10.1111/j.1365-2125.1994.tb04361.x

Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.

G J Veal 1, M J Wild 1, M G Barry 1, D J Back 1
PMCID: PMC1364775  PMID: 7833221

Abstract

1. Zidovudine (3'-azido-2',3'-dideoxythymidine; AZT; ZDV) is a dideoxynucleoside analogue active against human immunodeficiency virus (HIV). We are currently investigating the intracellular metabolism of ZDV to its putative active triphosphate form (ZDV triphosphate) in peripheral blood mononuclear cells and a lymphoblastoid cell line (h1A2v2). 2. Optimal conditions for intracellular phosphate formation in peripheral blood mononuclear cells occurred following a 72 h preincubation with the mitogen phytohaemagglutinin at a concentration of 10 micrograms ml-1. ZDV was metabolized predominantly to the monophosphate with smaller amounts of the di- and triphosphate anabolites. There was considerable inter- and intraindividual variability in phosphate formation in peripheral blood mononuclear cells. A similar pattern of phosphorylation was seen with the h1A2v2 lymphoblastoid cell line with ZDV monophosphate being the major metabolite. 3. With increasing interest in combination nucleoside analogue therapy in HIV-positive patients it is important to know if an interaction occurs at the level of phosphorylation. Neither dideoxyinosine (ddI) or dideoxycytidine (ddC) significantly reduced the intracellular phosphorylation of ZDV in either peripheral blood mononuclear cells or h1A2v2 cells. In contrast thymidine always gave marked inhibition (e.g. at 2.0 microM, 89% inhibition of total phosphate formation in peripheral blood mononuclear cells and 79% in h1A2v2 cells). It is, therefore, unlikely that in vivo either ddI or ddC will perturb ZDV phosphorylation.

Full text

PDF
323

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia G., Cooney D. A., Mitsuya H., Fridland A., Flora K. P., Hao Z., Dalal M., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol. 1987 Nov 15;36(22):3797–3800. doi: 10.1016/0006-2952(87)90440-0. [DOI] [PubMed] [Google Scholar]
  2. Arnér E. S., Valentin A., Eriksson S. Thymidine and 3'-azido-3'-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways. J Biol Chem. 1992 Jun 5;267(16):10968–10975. [PubMed] [Google Scholar]
  3. Barry M., Howe J. L., Back D. J., Swart A. M., Breckenridge A. M., Weller I. V., Beeching N., Nye F. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. Br J Clin Pharmacol. 1994 Jan;37(1):7–12. doi: 10.1111/j.1365-2125.1994.tb04231.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blakley R. L., Harwood F. C., Huff K. D. Cytostatic effects of 2',3'-dideoxyribonucleosides on transformed human hemopoietic cell lines. Mol Pharmacol. 1990 Feb;37(2):328–332. [PubMed] [Google Scholar]
  5. Collier A. C., Bozzette S., Coombs R. W., Causey D. M., Schoenfeld D. A., Spector S. A., Pettinelli C. B., Davies G., Richman D. D., Leedom J. M. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med. 1990 Oct 11;323(15):1015–1021. doi: 10.1056/NEJM199010113231502. [DOI] [PubMed] [Google Scholar]
  6. Cooper D. A., Gatell J. M., Kroon S., Clumeck N., Millard J., Goebel F. D., Bruun J. N., Stingl G., Melville R. L., González-Lahoz J. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med. 1993 Jul 29;329(5):297–303. doi: 10.1056/NEJM199307293290501. [DOI] [PubMed] [Google Scholar]
  7. Crespi C. L., Thilly W. G. Assay for gene mutation in a human lymphoblast line, AHH-1, competent for xenobiotic metabolism. Mutat Res. 1984 Sep;128(2):221–230. doi: 10.1016/0027-5107(84)90110-6. [DOI] [PubMed] [Google Scholar]
  8. Fischl M. A., Parker C. B., Pettinelli C., Wulfsohn M., Hirsch M. S., Collier A. C., Antoniskis D., Ho M., Richman D. D., Fuchs E. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1990 Oct 11;323(15):1009–1014. doi: 10.1056/NEJM199010113231501. [DOI] [PubMed] [Google Scholar]
  9. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  10. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  11. Freedman H. J., Gurtoo H. L., Minowada J., Paigen B., Vaught J. B. Aryl hydrocarbon hydroxylase in a stable human B-lymphocyte cell line, RPMI-1788, cultured in the absence of mitogen. Cancer Res. 1979 Nov;39(11):4605–4611. [PubMed] [Google Scholar]
  12. Freedman H. J., Parker N. B., Marinello A. J., Gurtoo H. L., Minowada J. Induction, inhibition, and biological properties of aryl hydrocarbon hydroxylase in a stable human B-lymphocyte cell line, RPMI-1788. Cancer Res. 1979 Nov;39(11):4612–4619. [PubMed] [Google Scholar]
  13. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gallo R. C., Salahuddin S. Z., Popovic M., Shearer G. M., Kaplan M., Haynes B. F., Palker T. J., Redfield R., Oleske J., Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500–503. doi: 10.1126/science.6200936. [DOI] [PubMed] [Google Scholar]
  15. Gao W. Y., Shirasaka T., Johns D. G., Broder S., Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest. 1993 May;91(5):2326–2333. doi: 10.1172/JCI116463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hamilton J. D., Hartigan P. M., Simberkoff M. S., Day P. L., Diamond G. R., Dickinson G. M., Drusano G. L., Egorin M. J., George W. L., Gordin F. M. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992 Feb 13;326(7):437–443. doi: 10.1056/NEJM199202133260703. [DOI] [PubMed] [Google Scholar]
  17. Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Marczyk K. S., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990 May;47(5):647–654. doi: 10.1038/clpt.1990.86. [DOI] [PubMed] [Google Scholar]
  18. Johnson M. A., Ahluwalia G., Connelly M. C., Cooney D. A., Broder S., Johns D. G., Fridland A. Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem. 1988 Oct 25;263(30):15354–15357. [PubMed] [Google Scholar]
  19. Kellam P., Boucher C. A., Larder B. A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1934–1938. doi: 10.1073/pnas.89.5.1934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kong X. B., Zhu Q. Y., Vidal P. M., Watanabe K. A., Polsky B., Armstrong D., Ostrander M., Lang S. A., Jr, Muchmore E., Chou T. C. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother. 1992 Apr;36(4):808–818. doi: 10.1128/aac.36.4.808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Larder B. A., Kellam P., Kemp S. D. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS. 1991 Feb;5(2):137–144. doi: 10.1097/00002030-199102000-00002. [DOI] [PubMed] [Google Scholar]
  22. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  23. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mitsuya H., Yarchoan R., Kageyama S., Broder S. Targeted therapy of human immunodeficiency virus-related disease. FASEB J. 1991 Jul;5(10):2369–2381. doi: 10.1096/fasebj.5.10.1712326. [DOI] [PubMed] [Google Scholar]
  25. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  26. Sandström E., Oberg B. Antiviral therapy in human immunodeficiency virus infections. Current status (Part II). Drugs. 1993 May;45(5):637–653. doi: 10.2165/00003495-199345050-00002. [DOI] [PubMed] [Google Scholar]
  27. Sommadossi J. P. Nucleoside analogs: similarities and differences. Clin Infect Dis. 1993 Feb;16 (Suppl 1):S7–15. doi: 10.1093/clinids/16.supplement_1.s7. [DOI] [PubMed] [Google Scholar]
  28. St Clair M. H., Richards C. A., Spector T., Weinhold K. J., Miller W. H., Langlois A. J., Furman P. A. 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother. 1987 Dec;31(12):1972–1977. doi: 10.1128/aac.31.12.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Starnes M. C., Cheng Y. C. Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem. 1987 Jan 25;262(3):988–991. [PubMed] [Google Scholar]
  30. Stretcher B. N., Pesce A. J., Murray J. A., Hurtubise P. E., Vine W. H., Frame P. T. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Ther Drug Monit. 1991 Jul;13(4):325–331. doi: 10.1097/00007691-199107000-00008. [DOI] [PubMed] [Google Scholar]
  31. Stretcher B. N., Pesce A. J., Wermeling J. R., Hurtubise P. E. In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes. Ther Drug Monit. 1990 Sep;12(5):481–489. doi: 10.1097/00007691-199009000-00013. [DOI] [PubMed] [Google Scholar]
  32. Szebeni J., Patel S. S., Hung K., Wahl L. M., Weinstein J. N. Effects of thymidine and uridine on the phosphorylation of 3'-azido-3'-deoxythymidine (zidovudine) in human mononuclear cells. Antimicrob Agents Chemother. 1991 Jan;35(1):198–200. doi: 10.1128/aac.35.1.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Törnevik Y., Jacobsson B., Britton S., Eriksson S. Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses. 1991 Sep;7(9):751–759. doi: 10.1089/aid.1991.7.751. [DOI] [PubMed] [Google Scholar]
  34. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  35. Zimmerman T. P., Mahony W. B., Prus K. L. 3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem. 1987 Apr 25;262(12):5748–5754. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES